L3VLUP
ProSign in

RXRX · ARGX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

RXRXARGX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • RXRX
  • ARGX
0102030202120222023202420252026
Holders and value by quarter
QuarterRXRXARGX
Q3 2020none listed holders, n.a.8 holders, $3.6bn
Q4 2020none listed holders, n.a.7 holders, $4.1bn
Q1 2021none listed holders, n.a.8 holders, $4.1bn
Q2 20212 holders, $763m9 holders, $4.6bn
Q3 20212 holders, $567m8 holders, $4.5bn
Q4 20212 holders, $417m9 holders, $5.3bn
Q1 20222 holders, $178m8 holders, $5.3bn
Q2 20222 holders, $193m13 holders, $6.5bn
Q3 20222 holders, $266m14 holders, $5.3bn
Q4 20222 holders, $215m13 holders, $5.5bn
Q1 20232 holders, $192m13 holders, $5.9bn
Q2 20232 holders, $223m18 holders, $6.6bn
Q3 20232 holders, $240m21 holders, $8.7bn
Q4 20232 holders, $442m17 holders, $6.3bn
Q1 20242 holders, $485m13 holders, $6.8bn
Q2 20243 holders, $415m14 holders, $7.9bn
Q3 20243 holders, $387m13 holders, $10.7bn
Q4 20242 holders, $387m14 holders, $12.3bn
Q1 20253 holders, $315m17 holders, $11.8bn
Q2 20252 holders, $289m18 holders, $10.8bn
Q3 20252 holders, $281m16 holders, $13.8bn
Q4 20252 holders, $250m16 holders, $14.8bn
Q1 20262 holders, $196m11 holders, $12.3bn
Q2 20262 holders, $238m14 holders, $15.0bn
RXRX

Recursion Pharmaceuticals Inc

Holders
2
Reported value
$387m
Buyers
0
Sellers
2

Breadth -2 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
ARGX

Argenx Se

Holders
14
Reported value
$12.3bn
Buyers
8
Sellers
6

Breadth +2 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q4 2024

Among the 16 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only RXRX (2)

ARK Investment Management LLC, Baillie Gifford & Co

Only ARGX (14)

Artisan Partners LP, Capital World Investors, Citadel Advisors LLC, D. E. Shaw & Co., Fidelity (FMR LLC), Holocene Advisors LP, Janus Henderson Group Ltd, Marshall Wace LLP, Moore Capital Management LP, Point72 Asset Management LP, T. Rowe Price Associates Inc, Voloridge Investment Management LLC, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →